Management of Neuropathic Pain with Methylprednisolone at the Site of Nerve Injury
Objective. Peripheral nerve blocks with methylprednisolone may provide effective pain therapy by decreasing ectopic neuronal discharge and the release of local inflammatory mediators at the site of nerve injury. In this study, we aimed to compare the efficacy of lidocaine alone with a combination o...
Gespeichert in:
| Veröffentlicht in: | Pain medicine (Malden, Mass.) Mass.), 2012-03, Vol.13 (3), p.443-451 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 451 |
|---|---|
| container_issue | 3 |
| container_start_page | 443 |
| container_title | Pain medicine (Malden, Mass.) |
| container_volume | 13 |
| creator | Eker, H. Evren Cok, Oya Yalcin Aribogan, Anis Arslan, Gulnaz |
| description | Objective. Peripheral nerve blocks with methylprednisolone may provide effective pain therapy by decreasing ectopic neuronal discharge and the release of local inflammatory mediators at the site of nerve injury. In this study, we aimed to compare the efficacy of lidocaine alone with a combination of depo‐methylprednisolone plus lidocaine in the management of neuropathic pain due to peripheral nerve damage.
Design. Randomized, double‐blind comparator trial
Setting. Group control (N = 44) received 0.5% lidocaine and group methylprednisolone (N = 44) received 80 mg depo‐methylprednisolone + 0.5% lidocaine proximal to the site of nerve injury with a total amount of 10–20 mL solution according to the type of peripheral nerve block with nerve stimulator.
Outcome Measures. Demographic data, preblock numerical rating scales (NRSs), the Leeds assessment of neuropathic symptoms and signs (LANSS0) score, accompanying symptoms, and analgesic requirements were recorded. Postblock NRS scores were noted following peripheral nerve block and after 3 months. LANSS1, accompanying symptoms, and analgesic requirements were also reevaluated 3 months after the injection.
Results. Demographic data, preblock NRS (8 ± 1.5 and 8.1 ± 1.2, respectively), postblock NRS (2.1 ± 1.2 and 2.4 ± 1.4, respectively), LANSS0 (18.4 ± 2.2 and 18.2 ± 2.1, respectively), and accompanying symptoms were comparable between groups. Scores for the methylprednisolone group were significantly improved at 3‐month postblock for NRS (2 ± 1.4 vs 5.2 ± 1.7) and LANSS1 scores (4.14 ± 2.7 vs 14.1 ± 2.8), accompanying symptoms, and analgesic requirements (P |
| doi_str_mv | 10.1111/j.1526-4637.2011.01323.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_929506545</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>929506545</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5103-a659c8afd98b2b1867928234b3ff35624db75e0114333e0d1aacaf8b89e35f3c3</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhiMEoh_wF5AlDpyS2p7YcQ4cUOmnum0pII6Wk0xYh2yy2E67--9JyLIHTvXFI_l5ZuzXUUQYTdi4TpqECS7jVEKWcMpYQhlwSDYvosP9wctdzSETB9GR9w2lTKYKXkcHnAMDoehh9LAwnfmJK-wC6Wtyi4Pr1yYsbUnuje3Ikw1LssCw3LZrh1Vnfd_2HRITSFgi-WoDzp57RHLVNYPbvole1ab1-Ha3H0ffz8--nV7GN3cXV6efbuJSMAqxkSIvlamrXBW8YEpmOVcc0gLqGoTkaVVkAsfHpQCAtGLGlKZWhcoRRA0lHEcf5r5r1_8e0Ae9sr7EtjUd9oPXOc8FlSIVI_n-P7LpB9eNl9NMsCyFXKqJUjNVut57h7VeO7sybqsZ1VPsutFTonpKV0-x67-x682ovtsNGIoVVnvxX84j8HEGnmyL22c31veLs6ka_Xj2rQ-42fvG_dIyGz9Y_7i90PAFruXnh2t9CX8A9CKefw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1517439685</pqid></control><display><type>article</type><title>Management of Neuropathic Pain with Methylprednisolone at the Site of Nerve Injury</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><source>Oxford Academic Journals (OUP)</source><creator>Eker, H. Evren ; Cok, Oya Yalcin ; Aribogan, Anis ; Arslan, Gulnaz</creator><creatorcontrib>Eker, H. Evren ; Cok, Oya Yalcin ; Aribogan, Anis ; Arslan, Gulnaz</creatorcontrib><description>Objective. Peripheral nerve blocks with methylprednisolone may provide effective pain therapy by decreasing ectopic neuronal discharge and the release of local inflammatory mediators at the site of nerve injury. In this study, we aimed to compare the efficacy of lidocaine alone with a combination of depo‐methylprednisolone plus lidocaine in the management of neuropathic pain due to peripheral nerve damage.
Design. Randomized, double‐blind comparator trial
Setting. Group control (N = 44) received 0.5% lidocaine and group methylprednisolone (N = 44) received 80 mg depo‐methylprednisolone + 0.5% lidocaine proximal to the site of nerve injury with a total amount of 10–20 mL solution according to the type of peripheral nerve block with nerve stimulator.
Outcome Measures. Demographic data, preblock numerical rating scales (NRSs), the Leeds assessment of neuropathic symptoms and signs (LANSS0) score, accompanying symptoms, and analgesic requirements were recorded. Postblock NRS scores were noted following peripheral nerve block and after 3 months. LANSS1, accompanying symptoms, and analgesic requirements were also reevaluated 3 months after the injection.
Results. Demographic data, preblock NRS (8 ± 1.5 and 8.1 ± 1.2, respectively), postblock NRS (2.1 ± 1.2 and 2.4 ± 1.4, respectively), LANSS0 (18.4 ± 2.2 and 18.2 ± 2.1, respectively), and accompanying symptoms were comparable between groups. Scores for the methylprednisolone group were significantly improved at 3‐month postblock for NRS (2 ± 1.4 vs 5.2 ± 1.7) and LANSS1 scores (4.14 ± 2.7 vs 14.1 ± 2.8), accompanying symptoms, and analgesic requirements (P < 0.0001).
Conclusions. Our results suggest that peripheral nerve block with 80 mg depo‐methylprednisolone plus 0.5% lidocaine provides effective management in the treatment of neuropathic pain due to peripheral nerve damage.</description><identifier>ISSN: 1526-2375</identifier><identifier>EISSN: 1526-4637</identifier><identifier>DOI: 10.1111/j.1526-4637.2011.01323.x</identifier><identifier>PMID: 22313580</identifier><identifier>CODEN: PMAEAP</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Anesthetics, Local - administration & dosage ; Depo-methylprednisolone ; Double-Blind Method ; Female ; Humans ; Lidocaine - administration & dosage ; Male ; Methylprednisolone - administration & dosage ; Middle Aged ; Nerve Block - methods ; Neuralgia - drug therapy ; Neuralgia - etiology ; Neuropathic Pain ; Neuroprotective Agents - administration & dosage ; Peripheral Nerve Blocks ; Peripheral Nerve Injuries - complications ; Peripheral Nerve Injuries - drug therapy ; Treatment Outcome</subject><ispartof>Pain medicine (Malden, Mass.), 2012-03, Vol.13 (3), p.443-451</ispartof><rights>Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5103-a659c8afd98b2b1867928234b3ff35624db75e0114333e0d1aacaf8b89e35f3c3</citedby><cites>FETCH-LOGICAL-c5103-a659c8afd98b2b1867928234b3ff35624db75e0114333e0d1aacaf8b89e35f3c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1526-4637.2011.01323.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1526-4637.2011.01323.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22313580$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eker, H. Evren</creatorcontrib><creatorcontrib>Cok, Oya Yalcin</creatorcontrib><creatorcontrib>Aribogan, Anis</creatorcontrib><creatorcontrib>Arslan, Gulnaz</creatorcontrib><title>Management of Neuropathic Pain with Methylprednisolone at the Site of Nerve Injury</title><title>Pain medicine (Malden, Mass.)</title><addtitle>Pain Med</addtitle><description>Objective. Peripheral nerve blocks with methylprednisolone may provide effective pain therapy by decreasing ectopic neuronal discharge and the release of local inflammatory mediators at the site of nerve injury. In this study, we aimed to compare the efficacy of lidocaine alone with a combination of depo‐methylprednisolone plus lidocaine in the management of neuropathic pain due to peripheral nerve damage.
Design. Randomized, double‐blind comparator trial
Setting. Group control (N = 44) received 0.5% lidocaine and group methylprednisolone (N = 44) received 80 mg depo‐methylprednisolone + 0.5% lidocaine proximal to the site of nerve injury with a total amount of 10–20 mL solution according to the type of peripheral nerve block with nerve stimulator.
Outcome Measures. Demographic data, preblock numerical rating scales (NRSs), the Leeds assessment of neuropathic symptoms and signs (LANSS0) score, accompanying symptoms, and analgesic requirements were recorded. Postblock NRS scores were noted following peripheral nerve block and after 3 months. LANSS1, accompanying symptoms, and analgesic requirements were also reevaluated 3 months after the injection.
Results. Demographic data, preblock NRS (8 ± 1.5 and 8.1 ± 1.2, respectively), postblock NRS (2.1 ± 1.2 and 2.4 ± 1.4, respectively), LANSS0 (18.4 ± 2.2 and 18.2 ± 2.1, respectively), and accompanying symptoms were comparable between groups. Scores for the methylprednisolone group were significantly improved at 3‐month postblock for NRS (2 ± 1.4 vs 5.2 ± 1.7) and LANSS1 scores (4.14 ± 2.7 vs 14.1 ± 2.8), accompanying symptoms, and analgesic requirements (P < 0.0001).
Conclusions. Our results suggest that peripheral nerve block with 80 mg depo‐methylprednisolone plus 0.5% lidocaine provides effective management in the treatment of neuropathic pain due to peripheral nerve damage.</description><subject>Anesthetics, Local - administration & dosage</subject><subject>Depo-methylprednisolone</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Lidocaine - administration & dosage</subject><subject>Male</subject><subject>Methylprednisolone - administration & dosage</subject><subject>Middle Aged</subject><subject>Nerve Block - methods</subject><subject>Neuralgia - drug therapy</subject><subject>Neuralgia - etiology</subject><subject>Neuropathic Pain</subject><subject>Neuroprotective Agents - administration & dosage</subject><subject>Peripheral Nerve Blocks</subject><subject>Peripheral Nerve Injuries - complications</subject><subject>Peripheral Nerve Injuries - drug therapy</subject><subject>Treatment Outcome</subject><issn>1526-2375</issn><issn>1526-4637</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v1DAQhiMEoh_wF5AlDpyS2p7YcQ4cUOmnum0pII6Wk0xYh2yy2E67--9JyLIHTvXFI_l5ZuzXUUQYTdi4TpqECS7jVEKWcMpYQhlwSDYvosP9wctdzSETB9GR9w2lTKYKXkcHnAMDoehh9LAwnfmJK-wC6Wtyi4Pr1yYsbUnuje3Ikw1LssCw3LZrh1Vnfd_2HRITSFgi-WoDzp57RHLVNYPbvole1ab1-Ha3H0ffz8--nV7GN3cXV6efbuJSMAqxkSIvlamrXBW8YEpmOVcc0gLqGoTkaVVkAsfHpQCAtGLGlKZWhcoRRA0lHEcf5r5r1_8e0Ae9sr7EtjUd9oPXOc8FlSIVI_n-P7LpB9eNl9NMsCyFXKqJUjNVut57h7VeO7sybqsZ1VPsutFTonpKV0-x67-x682ovtsNGIoVVnvxX84j8HEGnmyL22c31veLs6ka_Xj2rQ-42fvG_dIyGz9Y_7i90PAFruXnh2t9CX8A9CKefw</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Eker, H. Evren</creator><creator>Cok, Oya Yalcin</creator><creator>Aribogan, Anis</creator><creator>Arslan, Gulnaz</creator><general>Blackwell Publishing Inc</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Management of Neuropathic Pain with Methylprednisolone at the Site of Nerve Injury</title><author>Eker, H. Evren ; Cok, Oya Yalcin ; Aribogan, Anis ; Arslan, Gulnaz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5103-a659c8afd98b2b1867928234b3ff35624db75e0114333e0d1aacaf8b89e35f3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anesthetics, Local - administration & dosage</topic><topic>Depo-methylprednisolone</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Lidocaine - administration & dosage</topic><topic>Male</topic><topic>Methylprednisolone - administration & dosage</topic><topic>Middle Aged</topic><topic>Nerve Block - methods</topic><topic>Neuralgia - drug therapy</topic><topic>Neuralgia - etiology</topic><topic>Neuropathic Pain</topic><topic>Neuroprotective Agents - administration & dosage</topic><topic>Peripheral Nerve Blocks</topic><topic>Peripheral Nerve Injuries - complications</topic><topic>Peripheral Nerve Injuries - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eker, H. Evren</creatorcontrib><creatorcontrib>Cok, Oya Yalcin</creatorcontrib><creatorcontrib>Aribogan, Anis</creatorcontrib><creatorcontrib>Arslan, Gulnaz</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pain medicine (Malden, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eker, H. Evren</au><au>Cok, Oya Yalcin</au><au>Aribogan, Anis</au><au>Arslan, Gulnaz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Neuropathic Pain with Methylprednisolone at the Site of Nerve Injury</atitle><jtitle>Pain medicine (Malden, Mass.)</jtitle><addtitle>Pain Med</addtitle><date>2012-03</date><risdate>2012</risdate><volume>13</volume><issue>3</issue><spage>443</spage><epage>451</epage><pages>443-451</pages><issn>1526-2375</issn><eissn>1526-4637</eissn><coden>PMAEAP</coden><abstract>Objective. Peripheral nerve blocks with methylprednisolone may provide effective pain therapy by decreasing ectopic neuronal discharge and the release of local inflammatory mediators at the site of nerve injury. In this study, we aimed to compare the efficacy of lidocaine alone with a combination of depo‐methylprednisolone plus lidocaine in the management of neuropathic pain due to peripheral nerve damage.
Design. Randomized, double‐blind comparator trial
Setting. Group control (N = 44) received 0.5% lidocaine and group methylprednisolone (N = 44) received 80 mg depo‐methylprednisolone + 0.5% lidocaine proximal to the site of nerve injury with a total amount of 10–20 mL solution according to the type of peripheral nerve block with nerve stimulator.
Outcome Measures. Demographic data, preblock numerical rating scales (NRSs), the Leeds assessment of neuropathic symptoms and signs (LANSS0) score, accompanying symptoms, and analgesic requirements were recorded. Postblock NRS scores were noted following peripheral nerve block and after 3 months. LANSS1, accompanying symptoms, and analgesic requirements were also reevaluated 3 months after the injection.
Results. Demographic data, preblock NRS (8 ± 1.5 and 8.1 ± 1.2, respectively), postblock NRS (2.1 ± 1.2 and 2.4 ± 1.4, respectively), LANSS0 (18.4 ± 2.2 and 18.2 ± 2.1, respectively), and accompanying symptoms were comparable between groups. Scores for the methylprednisolone group were significantly improved at 3‐month postblock for NRS (2 ± 1.4 vs 5.2 ± 1.7) and LANSS1 scores (4.14 ± 2.7 vs 14.1 ± 2.8), accompanying symptoms, and analgesic requirements (P < 0.0001).
Conclusions. Our results suggest that peripheral nerve block with 80 mg depo‐methylprednisolone plus 0.5% lidocaine provides effective management in the treatment of neuropathic pain due to peripheral nerve damage.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>22313580</pmid><doi>10.1111/j.1526-4637.2011.01323.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1526-2375 |
| ispartof | Pain medicine (Malden, Mass.), 2012-03, Vol.13 (3), p.443-451 |
| issn | 1526-2375 1526-4637 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_929506545 |
| source | Wiley-Blackwell Journals; MEDLINE; Oxford Academic Journals (OUP) |
| subjects | Anesthetics, Local - administration & dosage Depo-methylprednisolone Double-Blind Method Female Humans Lidocaine - administration & dosage Male Methylprednisolone - administration & dosage Middle Aged Nerve Block - methods Neuralgia - drug therapy Neuralgia - etiology Neuropathic Pain Neuroprotective Agents - administration & dosage Peripheral Nerve Blocks Peripheral Nerve Injuries - complications Peripheral Nerve Injuries - drug therapy Treatment Outcome |
| title | Management of Neuropathic Pain with Methylprednisolone at the Site of Nerve Injury |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T22%3A40%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Neuropathic%20Pain%20with%20Methylprednisolone%20at%20the%20Site%20of%20Nerve%20Injury&rft.jtitle=Pain%20medicine%20(Malden,%20Mass.)&rft.au=Eker,%20H.%20Evren&rft.date=2012-03&rft.volume=13&rft.issue=3&rft.spage=443&rft.epage=451&rft.pages=443-451&rft.issn=1526-2375&rft.eissn=1526-4637&rft.coden=PMAEAP&rft_id=info:doi/10.1111/j.1526-4637.2011.01323.x&rft_dat=%3Cproquest_cross%3E929506545%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1517439685&rft_id=info:pmid/22313580&rfr_iscdi=true |